Renaissance Capital logo

Monte Rosa Therapeutics Priced, Nasdaq: GLUE

Preclinical biotech developing small molecule protein degraders for cancer and other diseases.

Industry: Health Care

Latest Trade: $27.83 +2.16 (+8.4%)

First Day Return: +11.5%

Return from IPO: +35.1%

Industry: Health Care

We are a biopharmaceutical company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically-relevant proteins. We have developed a proprietary protein degradation platform, called QuEEN, that enables us to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically-relevant proteins in a highly selective manner. We believe our small molecule MGDs may give us significant advantages over existing therapeutic modalities, including other protein degradation approaches, by allowing us to target proteins that have been considered undruggable or inadequately drugged. We focus on therapeutic targets backed by strong biological and genetic rationale with the goal of discovering and developing novel precision medicines. Our lead program is a series of selective and orally bioavailable GSPT1-directed MGD molecules, one of which we plan to evaluate in molecularly-defined subsets of Myc-driven cancers. We expect to select a development candidate in the second half of 2021, and submit an Investigational New Drug application, or IND, with the U.S. Food and Drug Administration, or the FDA, in the first half of 2022. Beyond our lead program, we have a number of discovery programs in our pipeline and intend to nominate at least two for lead optimization in 2021.
more less
IPO News for Monte Rosa Therapeutics
more
IPO Data
IPO File Date 06/04/2021
Offer Price $19.00
Price Range $17.00 - $19.00
Offer Shares (mm) 11.7
Deal Size ($mm) $222
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/23/2021
Offer Price $19.00
Price Range $17.00 - $19.00
Offer Shares (mm) 11.7
Deal Size ($mm) $222
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Boston, MA
Founded 2019
Employees 74
Website www.monterosatx.com